Torsten Schaller joined Heidelberg ImmunoTherapeutics in 2018 where he is currently serving as Director of Preclinical Development and CMC. In this function, he plays a key role in advancement and innovation of the company’s lead therapeutic compounds. He is responsible for managing preclinical development of drug candidates and translational research. He leads a strong network related to all CMC aspects of the company’s development projects and closely interacts with regulatory agencies and CDMOs. He has more than 15 years of experience in working with human pathogenic viruses as well as gene-transfer and expression systems such as lentiviral vectors in the research fields of virology, oncology and immunity. Before joining Heidelberg ImmunoTherapeutics he was group leader at the Department of Virology at the University Hospital Heidelberg, junior group leader at the Goethe University Frankfurt, and held postdoctoral positions at King’s College London and University College London. Torsten Schaller is author of over 40 scientific publications including articles in Nature, Science and Nature Medicine, and holds a PhD degree in Infection and Immunity from the University College London.